Particle.news
Download on the App Store
9 ARTICLES
·
31m ago

Pfizer Reportedly Nears $7.3 Billion Metsera Takeover

The reported bid signals a pivot to acquisitions following setbacks to Pfizer’s in-house weight-loss efforts.

The Pfizer logo is seen in this illustration taken August 3, 2025. REUTERS/Dado Ruvic/Illustration/File Photo
FILE - Pfizer signage is displayed at the Pfizer NYC Headquarters, Thursday, April 10, 2025, in New York. (AP Photo/Yuki Iwamura, File)
Image
Image

Overview

  • The Financial Times reports Pfizer is weighing a $47.50-per-share cash offer plus $22.50 tied to milestones, valuing Metsera at about $7.3 billion.
  • Reuters has not confirmed the report, and the companies did not comment, with an announcement described as possible as early as Monday unless talks fall through.
  • The $47.50 cash component represents roughly a 42.5% premium to Metsera’s Friday close of $33.32, which put its market value near $3.5 billion, according to LSEG.
  • Pfizer is seeking external obesity assets after discontinuing its danuglipron program over tolerability and liver-safety concerns as Eli Lilly and Novo Nordisk intensify competition.
  • Metsera’s lead injectable, MET-097i, showed about 11.3% average weight loss in a mid-stage trial, and the 2022-founded biotech is advancing injectable and oral GLP-1–based candidates.